Tatyana Feldman, MD

Tatyana Feldman, MD, director of the T cell program at the John Theurer Cancer Center, Hackensack Meridian Health, discusses the design and efficacy of the ECHELON-1 trial investigating brentuximab vedotin (Adcetris) with chemotherapy in patients with stage III or IV Hodgkin lymphoma after a 3-year update (NCT01712490).

This study was a large, randomized, multicenter study comparing the standard of care in this setting of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) versus brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (A+AVD) in patients with advanced stage disease. The primary end point of ECHELON-1 was modified progression-free survival (PFS), which was better in the A+AVD arm, according to Feldman.

were about 82% with brentuximab vedotin compared with 77% with the standard of care. Feldman says that even though that may be considered a small difference, any improvement in this field matters. The toxicity profile with A+AVD was also manageable for the patients in this trial, and there were no interventions for highly toxic problems. She believes that the long-term update is holding up with what was originally reported. The 3-year PFS rates were still close to 82% and 77%, with A+AVD at 83% and ABVD at 76%, respectively.

<< View more resources and information regarding lymphomas

Videos

Tatyana Feldman, MD, discusses the design and efficacy of the ECHELON-1 trial investigating brentuximab vedotin with chemotherapy in patients with stage III or IV Hodgkin lymphoma after a 3-year update.

ECHELON-1 Trial Shows Continued Efficacy Over Time in Hodgkin Lymphoma

Tatyana Feldman, MD, director of T cell program at the John Theurer Cancer Center, Hackensack Meridian Health, discusses how research is now building upon the positive results from the phase III ECHELON-1 study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

ECHELON-1 demonstrated the role of brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in patients with stage III or IV classical Hodgkin lymphoma. This regimen was previously approved by the FDA for the treatment of newly diagnosed patients with stage III/IV Hodgkin lymphoma, and new safety findings still support this indication.

To build on these positive results, Feldman says groups are designing clinical trials that incorporate novel therapies like brentuximab vedotin and PD-1 inhibitors as backbone therapy and in earlier-

Another larger study is evaluating the role of novel agents as treatment of patients with advanced Hodgkin lymphoma. Feldman says the field is evolving, and we will get answers in a few years when these data are available.

Tatyana Feldman, MD, director of T cell program at the John Theurer Cancer Center, Hackensack Meridian Health, discusses how research is now building upon the positive results from the phase III ECHELON-1 study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.<br />
&nbsp;

Research Builds On Positive ECHELON-1 Study in Hodgkin Lymphoma

Tatyana Feldman, MD,&nbsp;John Theurer Cancer Center, Hackensack University Medical Center, discusses the phase III Echelon-1 study, which found brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (AVD) demonstrated superior modified progression-free survival (PFS) versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma.&nbsp;

Tatyana Feldman, MD | Authors

Articles

ECHELON-1 Trial Shows Continued Efficacy Over Time in Hodgkin Lymphoma

Research Builds On Positive ECHELON-1 Study in Hodgkin Lymphoma

The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma